(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Key facts

Sponsor

Blueprint Medicines Corporation

Intervention

Elenestinib(drug)

Enrollment

534 enrolled

Eligibility

18 years · All sexes

Timeline

2021 – 2032

Study locations (30)

• University of Alabama at Birmingham, Birmingham, Alabama, United States
• David Geffen School of Medicine at UCLA, Los Angeles, California, United States
• Stanford Cancer Institute, Palo Alto, California, United States
• UCHealth Blood Disorders and Cell Therapies Center - Anschutz Medical Campus, Aurora, Colorado, United States
• Winship Cancer Institute, Emory University, Atlanta, Georgia, United States
• Brigham and Women's Hospital, Boston, Massachusetts, United States
• Michigan Medicine University of Michigan, Ann Arbor, Michigan, United States
• Mayo Clinic, Rochester, Minnesota, United States
• Roswell Park Cancer Institute, Buffalo, New York, United States
• Columbia University Medical Center, New York, New York, United States
• Duke Asthma, Allergy and Airway Center, Durham, North Carolina, United States
• University of Cincinnati Medical Center, Cincinnati, Ohio, United States
• The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States
• Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
• Princess Alexandra Hospital, Woolloongabba, Queensland, Australia
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Indolent systemic mastocytosis

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT07255638
  A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
  Blueprint Medicines Corporation
• ACTIVE NOT RECRUITINGPHASE2NCT05186753
  (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic Mastocytosis
  Cogent Biosciences, Inc.
• RECRUITINGPHASE2NCT04655118
  Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
  Telios Pharma, Inc.
• ACTIVE NOT RECRUITINGPHASE2NCT03731260
  (PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis
  Blueprint Medicines Corporation

See all trials for Indolent systemic mastocytosis →